Thumbnail
Access Restriction
Open

Author Ohashi, Toshio ♦ Yorozu, Atsunori ♦ Saito, Shiro ♦ Tanaka, Nobumichi ♦ Katayama, Norihisa ♦ Kojima, Shinsuke ♦ Maruo, Shinichiro ♦ Kikuchi, Takashi ♦ Dokiya, Takushi ♦ Fukushima, Masanori ♦ Yamanaka, Hidetoshi
Source United States Department of Energy Office of Scientific and Technical Information
Content type Text
Language English
Subject Keyword RADIOLOGY AND NUCLEAR MEDICINE ♦ BRACHYTHERAPY ♦ EXTERNAL BEAM RADIATION THERAPY ♦ IODINE 125 ♦ MEN ♦ NEOPLASMS ♦ PATIENTS ♦ PROSTATE ♦ RADIATION SOURCE IMPLANTS ♦ RECTUM ♦ RETENTION ♦ SYMPTOMS ♦ TOXICITY
Abstract Purpose: To assess, in a nationwide multi-institutional cohort study begun in 2005 and in which 6927 subjects were enrolled by 2010, the urinary and rectal toxicity profiles of subjects who enrolled during the first 2 years, and evaluate the toxicity profiles for permanent seed implantation (PI) and a combination therapy with PI and external beam radiation therapy (EBRT). Methods and Materials: Baseline data for 2339 subjects out of 2354 patients were available for the analyses. Toxicities were evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, and the International Prostate Symptom Scores were recorded prospectively until 36 months after radiation therapy. Results: Grade 2+ acute urinary toxicities developed in 7.36% (172 of 2337) and grade 2+ acute rectal toxicities developed in 1.03% (24 of 2336) of the patients. Grade 2+ late urinary and rectal toxicities developed in 5.75% (133 of 2312) and 1.86% (43 of 2312) of the patients, respectively. A higher incidence of grade 2+ acute urinary toxicity occurred in the PI group than in the EBRT group (8.49% vs 3.66%; P<.01). Acute rectal toxicity outcomes were similar between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late urinary toxicities were 6.04% versus 4.82% for the PI and the EBRT groups, respectively, with no significant differences between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late rectal toxicities were 0.90% versus 5.01% (P<.01) for the PI and the EBRT groups, respectively. The mean of the postimplant International Prostate Symptom Score peaked at 3 months, but it decreased to a range that was within 2 points of the baseline score, which was observed in 1625 subjects (69.47%) at the 1-year follow-up assessment. Conclusions: The acute urinary toxicities observed were acceptable given the frequency and retention, and the late rectal toxicities were more favorable than those of other studies.
ISSN 03603016
Educational Use Research
Learning Resource Type Article
Publisher Date 2015-09-01
Publisher Place United States
Journal International Journal of Radiation Oncology, Biology and Physics
Volume Number 93
Issue Number 1


Open content in new tab

   Open content in new tab